Why does cyclosporine lead to hyperkalemia, and what education should be provided to patients?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

Why does cyclosporine lead to hyperkalemia, and what education should be provided to patients?

Explanation:
Cyclosporine raises potassium mainly because it interferes with the kidney’s ability to excrete potassium, through effects on both renal hemodynamics and the hormonal control of potassium handling. By causing afferent arteriolar vasoconstriction and lowering glomerular filtration, it reduces the filtered load and secretion of potassium. It can also disrupt aldosterone action in the distal nephron, further decreasing potassium secretion. The net result is hyperkalemia risk, so education should focus on monitoring potassium and kidney function regularly, and managing potassium intake. Patients should follow any advised dietary potassium limits, avoid potassium-containing salt substitutes or potassium-sparing medications unless a clinician approves, and promptly report symptoms of high potassium (e.g., muscle weakness, tingling, fatigue, palpitations). They should also discuss with their clinician any other drugs that can raise potassium (like ACE inhibitors or ARBs) and keep up with lab tests and hydration as advised.

Cyclosporine raises potassium mainly because it interferes with the kidney’s ability to excrete potassium, through effects on both renal hemodynamics and the hormonal control of potassium handling. By causing afferent arteriolar vasoconstriction and lowering glomerular filtration, it reduces the filtered load and secretion of potassium. It can also disrupt aldosterone action in the distal nephron, further decreasing potassium secretion. The net result is hyperkalemia risk, so education should focus on monitoring potassium and kidney function regularly, and managing potassium intake. Patients should follow any advised dietary potassium limits, avoid potassium-containing salt substitutes or potassium-sparing medications unless a clinician approves, and promptly report symptoms of high potassium (e.g., muscle weakness, tingling, fatigue, palpitations). They should also discuss with their clinician any other drugs that can raise potassium (like ACE inhibitors or ARBs) and keep up with lab tests and hydration as advised.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy